Upload jain.csv

I cleaned up and concatenated the three CSV files that constitute the jain dataset. Column names have been cleaned to remove spaces and special characters.

jain.csv

@@ -0,0 +1,138 @@
+name,light_chain_class,type,original_mab_isotype_or_format,clinical_status,phagec,year_name_proposed,metadata_notes,vh,vl,lc_class,source,source_detaileda,disclaimers_and_known_issues,sequence_info_notes,hek_titer_mg_l,fab_tm_by_dsf_deg_c,sgac_sins_as100_nh4_2so4_mm,hic_retention_time_min_a,smac_retention_time_min_a,slope_for_accelerated_stability,poly_specificity_reagent_psr_smp_score_0_1,affinity_capture_self_interaction_nanoparticle_spectroscopy_ac_sins_delta_lambda_max_nm_average,cic_retention_time_min,csi_bli_delta_response_nm,elisa,bvp_elisa
+abituzumab,kappa,ZU,IgG2,Phase 2,False,2013,a Made with human isotype,QVQLQQSGGELAKPGASVKVSCKASGYTFSSFWMHWVRQAPGQGLEWIGYINPRSGYTEYNEIFRDKATMTTDTSTSTAYMELSSLRSEDTAVYYCASFLGRGAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWYQQKPGKAPKLLIYYTSKIHSGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQGNTFPYTFGQGTKVEIK,kappa,WHO-INN,PL109,,aPL and RL refer to WHO-INN publications for proposed and recommended lists,89.5554580290071,75.5,900.0,9.227,8.725,0.05563,0.1666661335637766,1.4588608195349846,8.620999999999997,0.0,1.1373747390491518,2.7207986688851915
+abrilumab,kappa,HU,IgG2,Phase 2,False,2014,"b Mixed chimeric, humanized LC and HC",QVQLVQSGAEVKKPGASVKVSCKVSGYTLSDLSIHWVRQAPGKGLEWMGGFDPQDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLKSEDTAVYYCATGSSSSWFDPWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFANYYCQQANSFPWTFGQGTKVEIK,kappa,WHO-INN,PL111,,,100.223196340551,71.0,900.0,9.413,8.699,0.02829,0.0,-0.9285255875093592,8.383999999999999,-0.02,1.124623995718366,1.8183028286189689
+adalimumab,kappa,HU,IgG1,Approved,True,1999,c Most as those molecules labeled Yes in the phage column were discovered and or optimized by phage display.  A small number of these were optimized by fragment-based phage techniques not involving display.,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIK,kappa,PDB,4NYL,,,134.928638213675,71.0,900.0,8.816,8.672,0.05069,0.0,1.062328361664409,8.865000000000002,-0.01,1.0755145072525718,1.4881863560732114
+alemtuzumab,kappa,ZU,IgG1,Approved,False,2000,,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIK,kappa,PDB,1BEY,,,144.653542801851,74.5,1000.0,8.769,8.672,0.06431,0.0,-0.7891989854609082,8.513999999999998,-0.02,1.1614913553524202,1.4642262895174707
+alirocumab,kappa,HU,IgG1,Approved,False,2012,,EVQLVESGGGLVQPGGSLRLSCAASGFTFNNYAMNWVRQAPGKGLDWVSTISGSGGTTNYADSVKGRFIISRDSSKHTLYLQMNSLRAEDTAVYYCAKDSNWGNFDLWGRGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYRSNNRNFLGWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYTTPYTFGQGTKLEIK,kappa,WHO-INN,PL107,,,69.2323451150256,71.5,900.0,9.036,8.681,0.0292,0.0,1.2305105389538458,8.757,-0.01,1.1962236913634507,2.179700499168053
+anifrolumab,kappa,HU,IgG1,Phase 3,False,2013,,EVQLVQSGAEVKKPGESLKISCKGSGYIFTNYWIAWVRQMPGKGLESMGIIYPGDSDIRYSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHDIEGFDYWGRGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFFAWYQQKPGQAPRLLIYGASSRATGIPDRLSGSGSGTDFTLTITRLEPEDFAVYYCQQYDSSAITFGQGTRLEIK,kappa,WHO-INN,PL109,,,82.046820982102,62.5,700.0,8.799,8.629,0.0708,0.0,-0.5613971335854627,8.488999999999999,-0.02,1.157449676152755,1.6232945091514144
+atezolizumab,kappa,ZU,IgG1-no-glyco,Approved,True,2014,,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIK,kappa,WHO-INN,PL112,,,164.085804300914,73.5,300.0,13.353,19.283,0.0556,0.0658123841612219,14.97112171419135,10.759999999999996,0.06,1.2947458411000836,6.1973782771535575
+bapineuzumab,kappa,ZU,IgG1,Phase 3,False,2005,,EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAPGKGLEWVASIRSGGGRTYYSDNVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRYDHYSGSSDYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCKSSQSLLDSDGKTYLNWLLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPRTFGQGTKVEIK,kappa,US Patent,US7582733,Conflicting literature sequences in FR3 of VH - AKNTLYLQMNSLRAEDTAV vs. AKNSLYLQMNSLRAEDTAL,,151.091649573153,73.0,1000.0,8.855,8.655,0.07017,0.0,-0.7342555803773684,8.619,0.06,1.2089498235875755,3.548752079866889
+basiliximab,kappa,XI,IgG1,Approved,False,1996,,QVQLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSS,QIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTKLEIK,kappa,PDB,1MIM,,,107.461587632875,60.5,0.0,9.578,8.576,0.0476,0.3971636878436583,28.757059110614296,9.448999999999996,0.0,1.2013275867288382,2.1385767790262173
+bavituximab,kappa,XI,IgG1,Phase 3,False,2006,,EVQLQQSGPELEKPGASVKLSCKASGYSFTGYNMNWVKQSHGKSLEWIGHIDPYYGDTSYNQKFRGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCVKGGYYGHWYFDVWGAGTTVTVSS,DIQMTQSPSSLSASLGERVSLTCRASQDIGSSLNWLQQGPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYVSSPPTFGAGTKLELK,kappa,WHO-INN,PL95,,,45.11027388324556,59.5,0.0,11.499,12.689,0.0404,0.5570368731420577,29.851202382637435,11.394999999999996,-0.01,1.3154556972115918,1.6928838951310858
+belimumab,lambda,HU,IgG1,Approved,True,2003,,QVQLQQSGAEVKKPGSSVRVSCKASGGTFNNNAINWVRQAPGQGLEWMGGIIPMFGTAKYSQNFQGRVAITADESTGTASMELSSLRSEDTAVYYCARSRDLLLFPHHALSPWGRGTMVTVSS,SSELTQDPAVSVALGQTVRVTCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCSSRDSSGNHWVFGGGTELTVL,lambda,US Patent,US8101181,,,10.4727274459097,60.0,800.0,10.461,9.267,0.1304,0.0,0.7712519507842107,8.588,-0.03,3.609534723535453,12.228951747088184
+benralizumab,kappa,ZU,IgG1,Phase 3,False,2009,,EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVIHWVRQRPGQGLAWMGYINPYNDGTKYNERFKGKVTITSDRSTSTVYMELSSLRSEDTAVYLCGREGIRYYGLLGDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCGTSEDIINYLNWYQQKPGKAPKLLIYHTSRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYTLPYTFGQGTKVEIK,kappa,WHO-INN,PL102,,,146.7126837302625,76.0,800.0,9.467,9.09,0.0243,0.3537118134191836,5.977932685387823,9.628,-0.01,1.2312629702928908,1.4247191011235956
+bevacizumab,kappa,ZU,IgG1,Approved,False,2000,,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,kappa,PDB,1BJ1,,,49.9785778269993,63.5,700.0,11.772,11.07,0.2198,0.0,0.790219867914591,9.822,-0.02,1.2859140710563497,2.7846921797004995
+bimagrumab,lambda,HU,IgG1,Phase 3,True,2012,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSSYINWVRQAPGQGLEWMGTINPVSGSTSYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGWFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNYVNWYQQHPGKAPKLMIYGVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCGTFAGGSYYGVFGGGTKLTVL,lambda,WHO-INN,PL108,,,150.238850504352,72.0,0.0,10.125,8.829,0.09126,0.6965555618675863,29.64509490013043,12.328,0.1,1.5486084368278836,5.327787021630615
+blosozumab,kappa,ZU,IgG4-CPPC,Phase 2,True,2011,,QVQLVQSGAEVKKPGASVKVSCKVSGFPIKDTFQHWVRQAPGKGLEWMGWSDPEIGDTEYASKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGDTTYKFDFWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVHTAVAWYQQKPGKAPKLLIYWASTRWTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSDYPWTFGGGTKVEIK,kappa,WHO-INN,PL105,,,120.00975163796,70.5,600.0,9.241,8.626,0.1252,0.2082434217055435,11.472475883134644,8.866000000000001,0.46,13.177765048787675,12.84792013311148
+bococizumab,kappa,ZU,IgG2,Phase 3,True,2013,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGEISPFGGRTNYNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARERPLYASDLWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQRYSLWRTFGQGTKLEIK,kappa,WHO-INN,PL110,,,95.7869214399117,67.0,0.0,10.179,9.108,0.067,0.7601842867698116,29.64509490013043,10.595,0.5,13.49645762735782,18.87720465890183
+brentuximab,kappa,XI,IgG1-ADC,Approved,False,2010,,QIQLQQSGPEVVKPGASVKISCKASGYTFTDYYITWVKQKPGQGLEWIGWIYPGSGNTKYNEKFKGKATLTVDTSSSTAFMQLSSLTSEDTAVYFCANYGNYWFAYWGQGTQVTVSA,DIVLTQSPASLAVSLGQRATISCKASQSVDFDGDSYMNWYQQKPGQPPKVLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPWTFGGGTKLEIK,kappa,WHO-INN,PL103,,,268.061982174822,72.0,800.0,10.535,8.683,-0.003086,0.2474876787715646,-0.5424265510343164,8.550999999999997,-0.03,4.211600067891459,2.2429284525790347
+briakinumab,lambda,HU,IgG1,Phase 3,True,2009,,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWGQGTMVTVSS,QSVLTQPPSVSGAPGQRVTISCSGSRSNIGSNTVKWYQQLPGTAPKLLIYYNDQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRYTHPALLFGTGTKVTVL,lambda,WHO-INN,PL101,,,121.99223381709,71.5,0.0,9.359,8.737,0.1054,0.5560592534086306,29.64509490013043,10.394,0.02,4.829995936621175,10.217637271214642
+brodalumab,kappa,HU,IgG2,Phase 3,False,2011,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTRYGISWVRQAPGQGLEWMGWISTYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARRQLYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWFQQKPGQAPRPLIYDASTRATGVPARFSGSGSGTDFTLTISSLQSEDFAVYYCQQYDNWPLTFGGGTKVEIK,kappa,WHO-INN,PL105,,,150.86258566485,74.5,900.0,9.079,8.743,0.01717,0.2654903000693104,11.207608587538331,8.971000000000002,-0.01,1.4751250398765592,2.9257903494176376
+canakinumab,kappa,HU,IgG1,Approved,False,2007,,QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIK,kappa,US Patent,US8105587,,,45.7249289561313,72.0,800.0,9.321,8.727,0.03791,0.0,0.6699380678068486,8.635,0.0,1.1954184187031964,2.545757071547422
+carlumab,kappa,HU,IgG1,Phase 2,True,2010,,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDGIYGELDFWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSDAYLAWYQQKPGQAPRLLIYDASSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYIQLHSFTFGQGTKVEIK,kappa,WHO-INN,PL104,,,243.323478252909,69.5,700.0,11.167,9.31,0.07491,0.2115823064950124,-0.4380321771813363,8.62,-0.02,2.7610833976722176,8.879201331114809
+certolizumab,kappa,ZU,FabPEG,Approved,False,2004,,EVQLVESGGGLVQPGGSLRLSCAASGYVFTDYGMNWVRQAPGKGLEWMGWINTYIGEPIYADSVKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCARGYRSYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVGTNVAWYQQKPGKAPKALIYSASFLYSGVPYRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPLTFGQGTKVEIK,kappa,US Patent,US7402662,,,186.709368605726,81.5,500.0,11.478,10.815,0.04289,0.0,0.1630953670850959,9.313999999999998,-0.01,1.1438183996579112,1.647920133111481
+cetuximab,kappa,XI,IgG1,Approved,False,1999,,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSA,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK,kappa,PDB,1YY8,,,109.160445482209,68.5,400.0,10.11,8.91,0.05474,0.0,1.2999612612528957,8.906,-0.04,1.0932803630555306,1.0855241264559068
+cixutumumab,lambda,HU,IgG1,Phase 2,True,2008,,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARAPLRFLEWSTQDHYYYYYMDVWGKGTTVTVSS,SSELTQDPAVSVALGQTVRITCQGDSLRSYYATWYQQKPGQAPILVIYGENKRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCKSRDGSGQHLVFGGGTKLTVL,lambda,WHO-INN,PL100,,,154.259630219969,73.5,0.0,11.76,10.723,0.1617,0.6570238935398882,29.64509490013043,9.664,0.38,3.766344319771545,11.90415973377704
+clazakizumab,kappa,ZU,IgG1,Phase 2,False,2012,,EVQLVESGGGLVQPGGSLRLSCAASGFSLSNYYVTWVRQAPGKGLEWVGIIYGSDETAYATSAIGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDSSDWDAKFNLWGQGTLVTVSS,AIQMTQSPSSLSASVGDRVTITCQASQSINNELSWYQQKPGKAPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQGYSLRNIDNAFGGGTKVEIK,kappa,WHO-INN,PL107,,,113.477346572884,69.5,800.0,9.568,8.871,0.05306,0.0,0.9300457109314908,8.729000000000001,-0.03,1.2815538046885984,4.11514143094842
+codrituzumab,kappa,ZU,IgG1,Phase 2,False,2013,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPGQGLEWMGALDPKTGDTAYSQKFKGRVTLTADKSTSTAYMELSSLTSEDTAVYYCTRFYSYTYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLVHSNRNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQNTHVPPTFGQGTKLEIK,kappa,WHO-INN,PL109,,,66.347407560354,73.0,1000.0,8.836,8.592,0.255,0.1479866030148163,-0.2857189383823876,8.453999999999999,-0.01,9.418865043753986,14.874542429284528
+crenezumab,kappa,ZU,IgG4-CPPC,Phase 3,False,2011,,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLELVASINSNGGSTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASGDYWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLVYSNGDTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK,kappa,WHO-INN,PL105,,,149.265976775631,72.0,700.0,10.031,8.703,0.04786,0.1049360677631279,6.37079988498525,8.899,0.0,1.1333962139863132,2.7806988352745425
+dacetuzumab,kappa,ZU,IgG1,Phase 2,False,2007,,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQAPGKGLEWVARVIPNAGGTSYNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYYCAREGIYWWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVEIK,kappa,WHO-INN,PL98,,,128.4522155567586,68.0,1000.0,8.466,8.614,0.0033,0.0,-0.0146761667615086,8.466999999999999,-0.04,1.0793259925499534,1.3352059925093631
+daclizumab,kappa,ZU,IgG1,Approved,False,1994,,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGQGTKVEVK,kappa,PDB,3NFP,,,245.10792344452,74.0,900.0,9.286,8.751,0.02794,0.0,-0.11058643018373,8.476,-0.02,1.1803655455457376,1.4143094841930115
+dalotuzumab,kappa,ZU,IgG1,Phase 2,False,2009,,QVQLQESGPGLVKPSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNYKPSLKDRVTISRDTSKNQFSLKLSSVTAADTAVYYCARYGRVFFDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSIVHSNGNTYLQWYLQKPGQSPQLLIYKVSNRLYGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPWTFGQGTKVEIK,kappa,US Patent,US7914784,Entries in WHO-INN documents (PL102 and RL64) have errors,,82.4173401920308,77.0,800.0,9.891,8.704,0.1466,0.3996481249533758,13.680590019875655,9.118,0.14,2.8986549663190946,8.253577371048253
+daratumumab,kappa,HU,IgG1,Approved,False,2009,,EVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIK,kappa,WHO-INN,PL101,,,233.33429841855,71.0,800.0,9.514,8.926,0.06363,0.0,1.80923047610872,8.854999999999999,0.0,1.2135841080988004,3.151414309484193
+denosumab,kappa,HU,IgG2,Approved,False,2005,,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIK,kappa,US Patent,US7364736,,,134.16784639303,69.5,1000.0,8.501,8.603,0.01043,0.0,5.90792488228362,8.811,0.11,5.917965726038389,17.74975041597338
+dinutuximab,kappa,XI,IgG1,Approved,False,2013,,EVQLLQSGPELEKPGASVMISCKASGSSFTGYNMNWVRQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKSSSTAYMHLKSLTSEDSAVYYCVSGMEYWGQGTSVTVSS,EIVMTQSPATLSVSPGERATLSCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK,kappa,WHO-INN,PL109,,,76.4288197947546,69.0,800.0,9.833,8.963,0.0098,0.3027408437092615,3.635205695940343,9.405,-0.02,1.0308868202823889,1.691760299625468
+drozitumab,lambda,HU,IgG1,Phase 2,True,2010,,EVQLVQSGGGVERPGGSLRLSCAASGFTFDDYAMSWVRQAPGKGLEWVSGINWQGGSTGYADSVKGRVTISRDNAKNSLYLQMNSLRAEDTAVYYCAKILGAGRGWYFDYWGKGTTVTVSS,SELTQDPAVSVALGQTVRITCSGDSLRSYYASWYQQKPGQAPVLVIYGANNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSADSSGNHVVFGGGTKLTVL,lambda,WHO-INN,PL103,,,22.0688960178219,63.0,0.0,9.29,8.716,0.02829,0.0,29.64509490013043,8.789999999999997,0.04,1.096796901037131,1.4795341098169716
+duligotuzumab,kappa,ZU,IgG1,Phase 2,True,2012,,EVQLVESGGGLVQPGGSLRLSCAASGFTLSGDWIHWVRQAPGKGLEWVGEISAAGGYTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARESRVSFEAAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQNIATDVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSEPEPYTFGQGTKVEIK,kappa,WHO-INN,PL107,,,192.582804385907,67.5,0.0,10.206,8.938,0.05514,0.3344399631930372,29.64509490013043,9.53,0.6,8.539747695728627,9.630615640599002
+dupilumab,kappa,HU,IgG4-CPPC,Phase 3,False,2012,,EVQLVESGGGLEQPGGSLRLSCAGSGFTFRDYAMTWVRQAPGKGLEWVSSISGSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRLSITIRPRYYGLDVWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSIGYNYLDWYLQKSGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGFYYCMQALQTPYTFGQGTKLEIK,kappa,WHO-INN,PL108,,,163.549147322201,76.5,700.0,10.159,9.009,0.02874,0.1468761136483416,10.804212296248885,9.751999999999995,-0.01,8.694358141880139,19.270549084858573
+eculizumab,kappa,ZU,IgG24,Approved,False,2002,,QVQLVQSGAEVKKPGASVKVSCKASGYIFSNYWIQWVRQAPGQGLEWMGEILPGSGSTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK,kappa,US Patent,US6355245,,,226.468531780092,66.0,700.0,10.41,9.277,0.008,0.0,0.043333,8.498999999999999,-0.04,0.9594280678530324,2.99550561797752
+efalizumab,kappa,ZU,IgG1,Approved,False,2001,,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGMIHPSDSETRYNQKFKDRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARGIYFYGTTYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASKTISKYLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPLTFGQGTKVEIK,kappa,PDB,3EOA,,,166.9923436829148,72.5,900.0,8.668,8.641,0.0,0.0,0.681275549075847,8.541999999999998,-0.02,0.9829102702195124,1.238202247191011
+eldelumab,kappa,HU,IgG1,Phase 2,False,2013,,QMQLVESGGGVVQPGRSLRLSCTASGFTFSNNGMHWVRQAPGKGLEWVAVIWFDGMNKFYVDSVKGRFTISRDNSKNTLYLEMNSLRAEDTAIYYCAREGDGSGIYYYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPIFTFGPGTKVDIK,kappa,WHO-INN,PL109,,,89.2530533728545,59.5,500.0,12.422,25.0,0.0998,0.0,1.2125200258514,10.155999999999995,-0.02,1.1090934181246197,1.7470881863560732
+elotuzumab,kappa,ZU,IgG1,Approved,False,2008,,EVQLVESGGGLVQPGGSLRLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVYYCARPDGNYWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVGIAVAWYQQKPGKVPKLLIYWASTRHTGVPDRFSGSGSGTDFTLTISSLQPEDVATYYCQQYSSYPYTFGQGTKVEIK,kappa,WHO-INN,PL100,,,213.190600445939,83.5,700.0,10.314,9.288,0.0,0.0,-0.2244689102300673,8.469,-0.03,0.978041767984992,1.2647940074906368
+emibetuzumab,kappa,ZU,IgG4-CPPC,Phase 2,True,2014,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGRVNPNRRGTTYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARANWLDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCSVSSSVSSIYLHWYQQKPGKAPKLLIYSTSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQVYSGYPLTFGGGTKVEIK,kappa,WHO-INN,PL111,,,98.7489181018493,71.5,0.0,9.638,8.684,0.04114,0.6431427690118359,29.64509490013043,9.528,0.06,3.3000830869543307,8.32945091514143
+enokizumab,kappa,ZU,IgG1,Phase 2,True,2010,,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSYYWIEWVRQAPGQGLEWMGEILPGSGTTNPNEKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARADYYGSDYVKFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQHVITHVTWYQQKPGKAPKLLIYGTSYSYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFYEYPLTFGGGTKVEIK,kappa,WHO-INN,PL104,,,239.819012639097,68.0,600.0,12.934,10.881,0.08966,0.1258283523473987,1.5335529590210266,9.028,-0.02,1.1734171887827547,3.2392678868552416
+epratuzumab,kappa,ZU,IgG1,Phase 3,False,1999,,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYWLHWVRQAPGQGLEWIGYINPRNDYTEYNQNFKDKATITADESTNTAYMELSSLRSEDTAFYFCARRDITTFYWGQGTTVTVSS,DIQLTQSPSSLSASVGDRVTMSCKSSQSVLYSANHKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYLSSWTFGGGTKLEIK,kappa,US Patent,US5789554,,,78.2305721688696,65.0,900.0,9.189,8.629,0.02629,0.130914724386105,3.0141872185730136,8.688999999999998,-0.01,1.4745521259964696,2.3427620632279536
+etrolizumab,kappa,ZU,IgG1,Phase 2,True,2010,,EVQLVESGGGLVQPGGSLRLSCAASGFFITNNYWGWVRQAPGKGLEWVGYISYSGSTSYNPSLKSRFTISRDTSKNTFYLQMNSLRAEDTAVYYCARTGSSGYFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASESVDDLLHWYQQKPGKAPKLLIKYASQSISGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGNSLPNTFGQGTKVEIK,kappa,WHO-INN,PL104,,,173.842456075648,76.0,900.0,9.322,8.77,0.2009,0.4203780747334936,2.01764560912522,8.767999999999999,-0.03,2.18207134775561,4.228951747088186
+evolocumab,lambda,HU,IgG2,Approved,False,2012,,EVQLVQSGAEVKKPGASVKVSCKASGYTLTSYGISWVRQAPGQGLEWMGWVSFYNGNTNYAQKLQGRGTMTTDPSTSTAYMELRSLRSDDTAVYYCARGYGMDVWGQGTTVTVSS,ESALTQPASVSGSPGQSITISCTGTSSDVGGYNSVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCNSYTSTSMVFGGGTKLTVL,lambda,WHO-INN,PL108,,,260.677127753984,65.0,700.0,10.355,9.13,0.0298,0.2043329600246225,2.236430607880717,9.254,-0.01,1.7544526538610823,1.7544093178036606
+farletuzumab,kappa,ZU,IgG1,Phase 3,False,2008,,EVQLVESGGGVVQPGRSLRLSCSASGFTFSGYGLSWVRQAPGKGLEWVAMISSGGSYTYYADSVKGRFAISRDNAKNTLFLQMDSLRPEDTGVYFCARHGDDPAWFAYWGQGTPVTVSS,DIQLTQSPSSLSASVGDRVTITCSVSSSISSNNLHWYQQKPGKAPKPWIYGTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSYPYMYTFGQGTKVEIK,kappa,WHO-INN,PL100,,,220.817623863655,75.5,800.0,9.491,9.065,0.006029,0.0,-0.5019252748286357,8.687,-0.01,1.073797051762033,1.3217970049916803
+fasinumab,kappa,HU,IgG4-CPPC,Phase 3,False,2012,,QVQLVQSGAEVKKPGASVKVSCKVSGFTLTELSIHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELTSLRSEDTAVYYCSTIFGVVTNFDNWGQGTLVTVSS,DIQMTQSPSSLSASAGDRVTITCRASQAIRNDLGWYQQKPGKAPKRLIYAAFNLQSGVPSRFSGSGSGTEFTLTISSLQPEDLASYYCQQYNRYPWTFGQGTKVEIK,kappa,WHO-INN,PL107,,,110.37448729273,71.0,900.0,10.026,8.715,0.06657,0.0,-0.6719270715475414,8.358999999999996,-0.02,1.1568614093693428,2.5271214642262896
+fezakinumab,lambda,HU,IgG1,Phase 2,True,2009,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWVGWINPYTGSAFYAQKFRGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREPEKFDSDDSDVWGRGTLVTVSS,QAVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYGVHWYQQLPGTAPKLLIYGDSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDNSLSGYVFGGGTQLTVL,lambda,WHO-INN,PL101,,,141.45349362403,69.0,600.0,11.798,13.709,0.06932,0.2647119030026545,2.5018396062184003,11.259999999999996,-0.0158,1.145612600241716,2.146422628951747
+ficlatuzumab,kappa,ZU,IgG1,Phase 2,False,2011,,QVQLVQPGAEVKKPGTSVKLSCKASGYTFTTYWMHWVRQAPGQGLEWIGEINPTNGHTNYNQKFQGRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNYVGSIFDYWGQGTLLTVSS,DIVMTQSPDSLAMSLGERVTLNCKASENVVSYVSWYQQKPGQSPKLLIYGASNRESGVPDRFSGSGSATDFTLTISSVQAEDVADYHCGQSYNYPYTFGQGTKLEIK,kappa,WHO-INN,PL105,,,249.025765193707,75.0,900.0,9.421,8.882,0.04614,0.0,-0.8937858080471764,8.488000000000001,-0.02,1.1338843592183554,1.2332778702163063
+figitumumab,kappa,HU,IgG2,Phase 3,False,2008,,EVQLLESGGGLVQPGGSLRLSCTASGFTFSSYAMNWVRQAPGKGLEWVSAISGSGGTTFYADSVKGRFTISRDNSRTTLYLQMNSLRAEDTAVYYCAKDLGWSDSYYYYYGMDVWGQGTTVTVSS,DIQMTQFPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASRLHRGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPCSFGQGTKLEIK,kappa,WHO-INN,PL100,,,119.916767611708,66.5,0.0,10.745,9.86,0.06446,0.3789575040877738,29.64509490013043,10.533,0.02,2.893762036891925,5.650582362728786
+fletikumab,kappa,HU,IgG4-CPPC,Phase 2,False,2013,,QVQLVQSGAEVKRPGASVKVSCKASGYTFTNDIIHWVRQAPGQRLEWMGWINAGYGNTQYSQNFQDRVSITRDTSASTAYMELISLRSEDTAVYYCAREPLWFGESSPHDYYGMDVWGQGTTVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,kappa,WHO-INN,PL110,,,220.376225219369,71.5,700.0,11.038,9.143,0.01897,0.0,-0.1254578092934176,8.473999999999998,-0.02,1.024451224557659,1.4083194675540764
+foralumab,kappa,HU,IgG1,Phase 2,False,2010,,QVQLVESGGGVVQPGRSLRLSCAASGFKFSGYGMHWVRQAPGKGLEWVAVIWYDGSKKYYVDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQMGYWHFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPLTFGGGTKVEIK,kappa,WHO-INN,PL103,,,174.435087528376,66.0,0.0,9.842,8.574,0.03766,0.3717153840610422,28.085284038746863,9.324,0.0,4.767633761341637,4.711480865224626
+fresolimumab,kappa,HU,IgG4,Phase 2,True,2009,,QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYYCASTLGLVLDAMDYWGQGTLVTVSS,ETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYADSPITFGQGTRLEIK,kappa,WHO-INN,PL101,,,166.036557375438,74.0,700.0,10.875,9.145,0.05526,0.0,-0.5150833213308835,8.466,-0.02,1.3001810808363088,3.5128119800332778
+fulranumab,kappa,HU,IgG2,Phase 3,False,2010,,EVQLVESGGGLVQPGGSLRLSCAASGFTLRSYSMNWVRQAPGKGLEWVSYISRSSHTIFYADSVKGRFTISRDNAKNSLYLQMDSLRDEDTAMYYCARVYSSGWHVSDYFDYWGQGILVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,kappa,WHO-INN,PL104,,,142.018924215224,68.5,900.0,9.328,9.342,0.07229,0.1876785614452756,11.560721017420292,9.345999999999998,0.0,1.8493078235489149,6.9231281198003325
+galiximab,lambda,XI,IgG1,Phase 2,False,2003,,QVQLQESGPGLVKPSETLSLTCAVSGGSISGGYGWGWIRQPPGKGLEWIGSFYSSSGNTYYNPSLKSQVTISTDTSKNQFSLKLNSMTAADTAVYYCVRDRLFSVVGMVYNNWFDVWGPGVLVTVSS,ESALTQPPSVSGAPGQKVTISCTGSTSNIGGYDLHWYQQLPGTAPKLLIYDINKRPSGISDRFSGSKSGTAASLAITGLQTEDEADYYCQSYDSSLNAQVFGGGTRLTVL,lambda,US Patent,US6113898,,,174.116871715928,67.5,600.0,12.198,14.77,0.03135,0.0,1.0937136443025857,8.87,-0.02,1.213663041666796,3.810316139767055
+ganitumab,kappa,HU,IgG1,Phase 3,True,2010,,QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARWTGRTDAFDIWGQGTMVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGQGTKVEIK,kappa,WHO-INN,PL103,,,229.439869516154,78.5,800.0,9.334,8.77,0.01174,0.5528448378515598,4.77483289417163,9.482,-0.01,1.29515577815994,4.907154742096505
+gantenerumab,kappa,HU,IgG1,Phase 3,True,2007,,QVELVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINASGTRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGKGNTHKPYGYVRYFDVWGQGTLVTVSS,DIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFATYYCLQIYNMPITFGQGTKVEIK,kappa,WHO-INN,PL97,,,162.65901137397,77.5,1000.0,9.004,8.487,0.06671,0.5526000371608855,6.957989416174726,8.709000000000001,0.1,13.820190243915356,22.746089850249582
+gemtuzumab,kappa,ZU,IgG4-ADC,Approved,False,2000,,EVQLVQSGAEVKKPGSSVKVSCKASGYTITDSNIHWVRQAPGQSLEWIGYIYPYNGGTDYNQKFKNRATLTVDNPTNTAYMELSSLRSEDTAFYYCVNGNPWLAYWGQGTLVTVSS,DIQLTQSPSTLSASVGDRVTITCRASESLDNYGIRFLTWFQQKPGKAPKLLMYAASNQGSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQTKEVPWSFGQGTKVEVK,kappa,US Patent,US5773001,,,171.299784622482,72.5,500.0,12.259,13.931,0.04534,0.0,1.0200510475198838,9.106,-0.01,1.080083574769414,1.6978369384359402
+gevokizumab,kappa,ZU,IgG2,Phase 3,False,2010,,QVQLQESGPGLVKPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAHIWWDGDESYNPSLKSRLTISKDTSKNQVSLKITSVTAADTAVYFCARNRYDPPWFVDWGQGTLVTVSS,DIQMTQSTSSLSASVGDRVTITCRASQDISNYLSWYQQKPGKAVKLLIYYTSKLHSGVPSRFSGSGSGTDYTLTISSLQQEDFATYFCLQGKMLPWTFGQGTKLEIK,kappa,WHO-INN,PL104,,,136.360640752103,71.5,1000.0,8.828,8.607,0.07129,0.0,-0.5147700660009676,8.578999999999999,-0.03,1.1800797913129024,1.9314475873544088
+girentuximab,kappa,XI,IgG1,Phase 3,False,2009,,DVKLVESGGGLVKLGGSLKLSCAASGFTFSNYYMSWVRQTPEKRLELVAAINSDGGITYYLDTVKGRFTISRDNAKNTLYLQMSSLKSEDTALFYCARHRSGYFSMDYWGQGTSVTVSS,DIVMTQSQRFMSTTVGDRVSITCKASQNVVSAVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADFFCQQYSNYPWTFGGGTKLEIK,kappa,WHO-INN,PL101,,,30.721829915697,63.0,1000.0,9.081,8.683,0.03154,0.0,-0.7518211058788499,8.524000000000001,-0.04,1.0901430323375536,1.393677204658902
+glembatumumab,kappa,HU,IgG2,Phase 2,False,2009,,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSFNYYWSWIRHHPGKGLEWIGYIYYSGSTYSNPSLKSRVTISVDTSKNQFSLTLSSVTAADTAVYYCARGYNWNYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVDNNLVWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPWTFGQGTKVEIK,kappa,WHO-INN,PL102,,,152.7123452567094,70.5,0.0,13.68,25.0,0.303,0.166106669274089,28.880634956572568,13.5,0.01,1.0632913221183808,2.215355805243446
+golimumab,kappa,HU,IgG1,Approved,False,2004,,QVQLVESGGGVVQPGRSLRLSCAASGFIFSSYAMHWVRQAPGNGLEWVAFMSYDGSNKKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGIAAGGNYYYYGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVYSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIK,kappa,US Patent,US7250165,,,163.238323057107,70.0,0.0,11.359,12.747,0.06274,0.2340078207264582,22.965397316589065,11.23,-0.01,1.3092959757129294,2.712146422628952
+guselkumab,lambda,HU,IgG1,Phase 3,True,2013,,EVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASWTDGLSLVVFGGGTKLTVL,lambda,WHO-INN,PL109,,,167.340128579443,69.5,700.0,11.403,9.195,0.1931,0.4693386329324933,3.3671961867062934,10.109,0.02,1.541175938153107,5.867554076539101
+ibalizumab,kappa,ZU,IgG4,Phase 3,False,2007,,QVQLQQSGPEVVKPGASVKMSCKASGYTFTSYVIHWVRQKPGQGLDWIGYINPYNDGTDYDEKFKGKATLTSDTSTSTAYMELSSLRSEDTAVYYCAREKDNYATGAWFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERVTMNCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQYYSYRTFGGGTKLEIK,kappa,WHO-INN,PL97,,,133.2826330317606,72.0,800.0,10.237,9.771,0.0393,0.0,-0.3393042568130033,8.659999999999997,-0.03,0.9931422443300496,1.1262172284644194
+imgatuzumab,kappa,ZU,IgG1,Phase 2,False,2012,,QVQLVQSGAEVKKPGSSVKVSCKASGFTFTDYKIHWVRQAPGQGLEWMGYFNPNSGYSTYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARLSPGGYYVMDAWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGINNYLNWYQQKPGKAPKRLIYNTNNLQTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSFPTFGQGTKLEIK,kappa,WHO-INN,PL107,,,187.708496613097,71.5,800.0,10.09,8.898,0.06543,0.0,0.8938737657378684,8.994000000000002,-0.01,5.014940855575772,11.774376039933443
+infliximab,kappa,XI,IgG1,Approved,False,1997,,EVKLEESGGGLVQPGGSMKLSCVASGFIFSNHWMNWVRQSPEKGLEWVAEIRSKSINSATHYAESVKGRFTISRDDSKSAVYLQMTDLRTEDTGVYYCSRNYYGSTYDYWGQGTTLTVSS,DILLTQSPAILSVSPGERVSFSCRASQFVGSSIHWYQQRTNGSPRLLIKYASESMSGIPSRFSGSGSGTDFTLSINTVESEDIADYYCQQSHSWPFTFGSGTNLEVK,kappa,PDB,4G3Y,,,6.58114599258111,64.5,0.0,10.36,8.888,0.1812,0.0,29.64509490013043,9.011,0.05,1.03683210868708,1.3717138103161397
+inotuzumab,kappa,ZU,IgG4-ADC,Phase 3,False,2004,,EVQLVQSGAEVKKPGASVKVSCKASGYRFTNYWIHWVRQAPGQGLEWIGGINPGNNYATYRRKFQGRVTMTADTSTSTVYMELSSLRSEDTAVYYCTREGYGNYGAWFAYWGQGTLVTVSS,DVQVTQSPSSLSASVGDRVTITCRSSQSLANSYGNTFLSWYLHKPGKAPQLLIYGISNRFSGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCLQGTHQPYTFGQGTKVEIK,kappa,US Patent,US7355011,,,169.767061734025,83.0,800.0,9.717,9.052,0.02517,0.2500082588538663,4.029670812855627,9.294999999999996,0.01,3.180204855314145,5.39567387687188
+ipilimumab,kappa,HU,IgG1,Approved,False,2005,,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,kappa,US Patent,US6984720,,,169.561868339531,73.0,400.0,11.57,12.981,0.03963,0.2296311389276418,10.41309875157468,10.941000000000004,0.01,1.0524254712559482,1.691846921797005
+ixekizumab,kappa,ZU,IgG4-CPPC,Approved,True,2011,,QVQLVQSGAEVKKPGSSVKVSCKASGYSFTDYHIHWVRQAPGQGLEWMGVINPMYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGNTYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGQGTKLEIK,kappa,WHO-INN,PL105,,,97.2774327422424,83.0,500.0,10.936,9.082,0.1614,0.8098172517111,19.952342859717294,9.635999999999996,0.11,8.797459757651835,10.398668885191348
+lampalizumab,kappa,ZU,Fab,Phase 3,False,2012,,EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSS,DIQVTQSPSSLSASVGDRVTITCITSTDIDDDMNWYQQKPGKVPKLLISGGNTLRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIK,kappa,WHO-INN,PL107,,,187.075401757929,67.0,800.0,9.25,8.765,0.08749,0.0,0.4941767225867576,8.455,-0.03,1.108847668199257,1.340432612312812
+lebrikizumab,kappa,ZU,IgG4-CPPC,Phase 3,False,2009,,QVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALEWLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYYPYAMDNWGQGSLVTVSS,DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPRTFGGGTKVEIK,kappa,WHO-INN,PL101,,,61.607125235924,66.0,500.0,12.381,15.71,0.0047,0.0,0.2553262101188233,9.070999999999996,-0.04,0.962254096761123,1.4561797752808987
+lenzilumab,kappa,HU,IgG1,Phase 2,True,2014,,QVQLVQSGAEVKKPGASVKVSCKASGYSFTNYYIHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCVRRQRFPYYFDYWGQGTLVTVSS,EIVLTQSPATLSVSPGERATLSCRASQSVGTNVAWYQQKPGQAPRVLIYSTSSRATGITDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFNKSPLTFGGGTKVEIK,kappa,WHO-INN,PL111,,,184.74275801653,74.0,0.0,8.722,8.605,0.03277,0.6551284845893702,29.64509490013043,10.121999999999998,0.02,14.459031329082327,19.604658901830284
+lintuzumab,kappa,ZU,IgG1,Phase 3,False,1996,,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYNMHWVRQAPGQGLEWIGYIYPYNGGTGYNQKFKSKATITADESTNTAYMELSSLRSEDTAVYYCARGRPAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASESVDNYGISFMNWFQQKPGKAPKLLIYAASNQGSGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQSKEVPWTFGQGTKVEIK,kappa,US Patent,US5530101,,,229.970847955366,75.5,700.0,10.874,9.428,0.048,0.0,0.8859881084878957,8.933000000000002,-0.02,1.045706347729163,1.254575707154742
+lirilumab,kappa,HU,IgG4-CPPC,Phase 2,False,2012,,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSFYAISWVRQAPGQGLEWMGGFIPIFGAANYAQKFQGRVTITADESTSTAYMELSSLRSDDTAVYYCARIPSGSYYYDYDMDVWGQGTTVTVSS,EIVLTQSPVTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWMYTFGQGTKLEIK,kappa,WHO-INN,PL107,,,270.480296548054,70.0,300.0,25.0,25.0,0.00174,0.1829138419950332,20.998948134543895,10.562,0.04,1.2695558152902904,3.5494176372712145
+lumiliximab,kappa,XI,IgG1,Phase 2,False,2004,,EVQLVESGGGLAKPGGSLRLSCAASGFRFTFNNYYMDWVRQAPGQGLEWVSRISSSGDPTWYADSVKGRFTISRENANNTLFLQMNSLRAEDTAVYYCASLTTGSDSWGQGVLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIRYYLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTEFTLTVSSLQPEDFATYYCLQVYSTPRTFGQGTKVEIK,kappa,US Patent,US6893636,,,86.2730393740933,64.5,800.0,9.545,8.782,0.06686,0.1448969343845078,1.4435487891722294,8.815,-0.02,1.1379105646124137,2.2183028286189685
+matuzumab,kappa,ZU,IgG1,Phase 2,False,2003,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHWMHWVRQAPGQGLEWIGEFNPSNGRTNYNEKFKSKATMTVDTSTNTAYMELSSLRSEDTAVYYCASRDYDYDGRYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVTYMYWYQQKPGKAPKLLIYDTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSHIFTFGQGTKVEIK,kappa,PDB,3C08,,,224.328820629927,72.0,900.0,9.84,8.834,0.0164,0.0,-0.9272078922528316,8.635,-0.03,1.0598553668783508,1.0276206322795345
+mavrilimumab,lambda,HU,IgG4,Phase 2,True,2009,,QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFDPEENEIVYAQRFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCAIVGSFSPLTLGLWGQGTMVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSGSNIGAPYDVSWYQQLPGTAPKLLIYHNNKRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCATVEAGLSGSVFGGGTKLTVL,lambda,WHO-INN,PL102,,,150.548852590834,68.5,700.0,10.296,8.671,0.04903,0.0,-0.7787536595715207,8.496,-0.01,1.2130818227431417,2.161730449251248
+mepolizumab,kappa,ZU,IgG1AA-mut,Approved,False,1999,,QVTLRESGPALVKPTQTLTLTCTVSGFSLTSYSVHWVRQPPGKGLEWLGVIWASGGTDYNSALMSRLSISKDTSRNQVVLTMTNMDPVDTATYYCARDPPSSLLRLDYWGRGTPVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNVHSFPFTFGGGTKLEIK,kappa,US Patent,US5693323,,,221.475176577629,78.5,900.0,9.238,8.816,0.04451,0.0,-0.9566370687348312,8.408,-0.04,1.131191260106393,1.0515806988352745
+mogamulizumab,kappa,ZU,IgG1-glyco,Approved,False,2010,,EVQLVESGGDLVQPGRSLRLSCAASGFIFSNYGMSWVRQAPGKGLEWVATISSASTYSYYPDSVKGRFTISRDNAKNSLYLQMNSLRVEDTALYYCGRHSDGNFAFGYWGQGTLVTVSS,DVLMTQSPLSLPVTPGEPASISCRSSRNIVHINGDTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSLLPWTFGQGTKVEIK,kappa,WHO-INN,PL104,,,89.7679294665026,68.5,800.0,9.641,8.82,0.03631,0.0,-0.5117615211688626,8.630999999999998,-0.02,1.1182820677553225,2.1657237936772047
+motavizumab,kappa,ZU,IgG1,Phase 3,True,2006,,QVTLRESGPALVKPTQTLTLTCTFSGFSLSTAGMSVGWIRQPPGKALEWLADIWWDDKKHYNPSLKDRLTISKDTSKNQVVLKVTNMDPADTATYYCARDMIFNFYFDVWGQGTTVTVSS,DIQMTQSPSTLSASVGDRVTITCSASSRVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKVEIK,kappa,PDB,3IXT,,,133.551594970658,86.0,800.0,9.689,8.82,0.04454,0.0,2.5227630302447666,8.660000000000002,-0.01,1.22954028386928,5.360399334442596
+muromonab,kappa,XIa,IgG2a,Approved,False,1988,,QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS,QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEIK,kappa,PDB,1SY6,Last residue of LC variable region changed from N to K. N would create a NRT N-glycosylation site when joined to human CK sequence,,113.522880356409,74.5,1000.0,8.899,8.578,0.03829,0.1758916346908985,2.311512650397803,9.047999999999996,0.01,1.408897007528137,3.9374376039933447
+natalizumab,kappa,ZU,IgG4,Approved,False,1998,,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIK,kappa,US Patent,US5840299,,,251.745704994274,79.5,900.0,9.7,8.843,0.01877,0.0,0.8228838815638237,8.763999999999998,-0.01,1.0639936735398734,1.5247920133111483
+necitumumab,kappa,HU,IgG1,Approved,True,2008,,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSS,EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIK,kappa,WHO-INN,PL100,,,198.599891054805,76.5,600.0,10.807,9.9,0.0204,0.0,1.3005776956421913,8.770999999999999,-0.02,1.045455831771032,1.3104825291181363
+nimotuzumab,kappa,ZU,IgG1,Approved,False,2005,,QVQLQQSGAEVKKPGSSVKVSCKASGYTFTNYYIYWVRQAPGQGLEWIGGINPTSGGSNFNEKFKTRVTITADESSTTAYMELSSLRSEDTAFYFCTRQGLWFDSDGRGFDFWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQNIVHSNGNTYLDWYQQTPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCFQYSHVPWTFGQGTKLQIT,kappa,PDB,3GKW,,,15.1316498281991,65.5,900.0,25.0,8.884,0.04357,0.0,-0.5855046313570632,8.464,-0.02,1.3186788480077605,3.424292845257904
+nivolumab,kappa,HU,IgG4-CPPC,Approved,False,2012,,QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIK,kappa,WHO-INN,PL107,,,178.809228510513,66.0,900.0,9.023,8.655,0.02743,0.1351754591387035,2.4180401288815534,8.853,-0.01,1.153877024631619,1.3244592346089852
+obinutuzumab,kappa,ZU,IgG1-glyco,Approved,False,2009,,QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS,DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK,kappa,WHO-INN,RL65,,,176.441448316105,73.0,600.0,10.641,8.964,0.0128,0.1127853019851912,1.83157297498583,8.799999999999999,-0.01,0.9505575375720098,1.6295880149812734
+ocrelizumab,kappa,ZU,IgG1,Phase 3,False,2005,,EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSNSYWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKPLIYAPSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSFNPPTFGQGTKVEIK,kappa,US Patent,US8562992,,,137.774414120228,70.5,300.0,9.911,8.83,0.0237,0.0,17.8819936959764,9.531999999999998,0.01,1.1284919906404225,1.6726591760299625
+ofatumumab,kappa,HU,IgG1,Approved,False,2005,,EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIK,kappa,PDB,3GIZ,,,249.752167259925,68.0,800.0,9.729,9.524,0.02874,0.0,1.2096991584336332,9.248,-0.02,1.1221425835603067,1.1767054908485857
+olaratumab,kappa,HU,IgG1,Phase 2,False,2010,,QLQLQESGPGLVKPSETLSLTCTVSGGSINSSSYYWGWLRQSPGKGLEWIGSFFYTGSTYYNPSLRSRLTISVDTSKNQFSLMLSSVTAADTAVYYCARQSTYYYGSGNYYGWFDRWDQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPAFGQGTKVEIK,kappa,WHO-INN,PL103,,,141.936047698606,62.5,700.0,10.609,8.957,0.2885,0.4831425745388005,0.3103945521038816,9.417,-0.02,1.3160671759946407,2.584359400998336
+olokizumab,kappa,ZU,IgG4-CPPC,Phase 2,False,2010,,EVQLVESGGGLVQPGGSLRLSCAASGFNFNDYFMNWVRQAPGKGLEWVAQMRNKNYQYGTYYAESLEGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARESYYGFTSYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDIGISLSWYQQKPGKAPKLLIYNANNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQHNSAPYTFGQGTKLEIK,kappa,WHO-INN,PL103,,,115.258271448835,69.0,700.0,9.908,8.973,0.04469,0.0,-0.5026150619501847,8.749,-0.03,1.10536901058665,1.2292845257903493
+omalizumab,kappa,ZU,IgG1,Approved,False,2000,,EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYNPSLKGRITISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIK,kappa,PDB,2XA8,CDR-H2 has V to L mutation (unintended),,150.447109488797,77.5,800.0,9.519,8.744,0.04511,0.0,-0.4382784241093604,8.537999999999998,-0.02,1.116104955964963,1.1660565723793677
+onartuzumab,kappa,ZU,IgG1-One-armed,Phase 3,False,2010,,EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRFNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIK,kappa,WHO-INN,PL104,,,147.933138230081,80.0,800.0,9.919,8.869,0.04311,0.0,-0.0466620425648519,8.911,-0.02,1.1192805146585436,1.1866888519134775
+otelixizumab,lambda,XIZUb,IgG1-no-glyco,Phase 3,False,2007,,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFPMAWVRQAPGKGLEWVSTISTSGGRTYYRDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKFRQYSGGFDYWGQGTLVTVSS,DIQLTQPNSVSTSLGSTVKLSCTLSSGNIENNYVHWYQLYEGRSPTTMIYDDDKRPDGVPDRFSGSIDRSSNSAFLTIHNVAIEDEAIYFCHSYVSSFNVFGGGTKLTVL,lambda,WHO-INN,PL98,,,152.082452769047,75.5,1000.0,9.082,8.72,0.08814,0.0,4.438287496308697,8.719,-0.02,1.1278218851815427,1.3976705490848589
+otlertuzumab,kappa,ZU,scFv-Fc,Phase 2,False,2013,,EVQLVQSGAEVKKPGESLKISCKGSGYSFTGYNMNWVRQMPGKGLEWMGNIDPYYGGTTYNRKFKGQVTISADKSISTAYLQWSSLKASDTAMYYCARSVGPFDSWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASENVYSYLAWYQQKPGQAPRLLIYFAKTLAEGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHHSDNPWTFGQGTKVEIK,kappa,WHO-INN,PL110,,,149.600653819379,68.5,600.0,10.959,10.267,0.07229,0.0,2.2609834310984502,9.516,-0.03,1.171753052308772,1.7816971713810317
+ozanezumab,kappa,ZU,IgG1,Phase 2,False,2012,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGNINPSNGGTNYNEKFKSKATMTRDTSTSTAYMELSSLRSEDTAVYYCELMQGYWGQGTLVTVSS,DIVMTQSPLSNPVTLGQPVSISCRSSKSLLYKDGKTYLNWFLQRPGQSPQLLIYLMSTRASGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCQQLVEYPLTFGQGTKLEIK,kappa,WHO-INN,PL108,,,97.0746878906631,67.0,0.0,10.034,8.632,0.05569,0.7713140231818809,27.69233206640333,9.045999999999998,0.45,2.0293580052025075,4.452579034941763
+palivizumab,kappa,ZU,IgG1,Approved,False,1998,,QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKDYNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARSMITNWYFDVWGAGTTVTVSS,DIQMTQSPSTLSASVGDRVTITCKCQLSVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKLEIK,kappa,US Patent,US7704505,,,243.119697931277,79.5,900.0,9.332,8.705,0.03666,0.0,-0.852684669073482,8.490999999999998,-0.03,1.11884672778966,2.876539101497504
+panitumumab,kappa,HU,IgG2,Approved,False,2004,,QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK,kappa,US Patent,US8628773,,,179.58785735722,78.5,900.0,9.479,8.799,0.03631,0.0,-1.0846051804108647,8.42,-0.03,1.0620884253110507,1.1826955074875207
+panobacumab,kappa,HU,IgM,Phase 2,False,2008,,EEQVVESGGGFVQPGGSLRLSCAASGFTFSPYWMHWVRQAPGKGLVWVSRINSDGSTYYADSVKGRFTISRDNARNTLYLQMNSLRAEDTAVYYCARDRYYGPEMWGQGTMVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGGGTKVEIK,kappa,WHO-INN,PL100,,,107.597685805881,69.0,900.0,9.827,8.85,0.02071,0.0,-0.4155766600895652,8.992000000000003,-0.01,1.212666778322873,1.896838602329451
+parsatuzumab,kappa,ZU,IgG1,Phase 2,True,2012,,EVQLVESGGGLVQPGGSLRLSCAASGYTFIDYYMNWVRQAPGKGLEWVGDINLDNSGTHYNQKFKGRFTISRDKSKNTAYLQMNSLRAEDTAVYYCAREGVYHDYDDYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSQSLVHINAITYLHWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCGQSTHVPLTFGQGTKVEIK,kappa,WHO-INN,PL107,,,40.0193274662591,64.5,900.0,9.109,8.781,0.08654,0.1344436107271991,7.400358629404036,8.650999999999998,0.12,10.046526919824307,17.395673876871882
+patritumab,kappa,HU,IgG1,Phase 3,False,2011,,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVETSKNQFSLKLSSVTAADTAVYYCARDKWTWYFDLWGRGTLVTVSS,DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSNRNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPRTFGQGTKVEIK,kappa,WHO-INN,PL106,,,68.7744200744969,71.5,600.0,10.15,9.321,0.05371,0.520072725150479,13.086408099747162,9.445,0.04,2.346216519385749,4.346089850249584
+pembrolizumab,kappa,ZU,IgG4-CPPC,Approved,False,2013,,QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIK,kappa,WHO-INN,RL72,,,64.9089832561903,66.0,500.0,11.073,13.477,0.0334,0.3004254416492691,5.622346926584057,10.918,0.01,1.277062460201701,2.234276206322796
+pertuzumab,kappa,ZU,IgG1,Approved,False,2003,,EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIK,kappa,PDB,1S78,,,31.426915083696,78.5,700.0,10.112,8.913,0.03917,0.0,-0.2038247903172226,8.597,-0.04,1.2135825800677662,1.691846921797005
+pinatuzumab,kappa,ZU,IgG1-ADC,Phase 2,False,2012,,EVQLVESGGGLVQPGGSLRLSCAASGYEFSRSWMNWVRQAPGKGLEWVGRIYPGDGDTNYSGKFKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDGSSWDWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSIVHSVGNTFLEWYQQKPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFQGSQFPYTFGQGTKVEIK,kappa,WHO-INN,PL108,,,130.580856755494,79.0,800.0,9.224,8.827,0.06846,0.0113662831220609,0.5895214803654546,8.774000000000001,-0.02,1.2721713049670622,2.4851913477537435
+polatuzumab,kappa,ZU,IgG1,Phase 2,True,2012,,EVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPLTFGQGTKVEIK,kappa,WHO-INN,PL108,,,225.055164066148,74.0,1000.0,8.763,8.67,0.05931,0.0,-1.0031675074379405,8.263999999999998,-0.05,1.3625371953152638,3.622628951747088
+ponezumab,kappa,ZU,IgG2,Phase 2,True,2010,,QVQLVQSGAEVKKPGASVKVSCKASGYYTEAYYIHWVRQAPGQGLEWMGRIDPATGNTKYAPRLQDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCASLYSLPVYWGQGTTVTVSS,DVVMTQSPLSLPVTLGQPASISCKSSQSLLYSDAKTYLNWFQQRPGQSPRRLIYQISRLDPGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHYPVLFGQGTRLEIK,kappa,WHO-INN,PL104,,,16.9578603061903,61.0,800.0,10.499,9.004,0.1568,0.0743593405423292,-0.2399076202624778,8.678999999999997,-0.03,3.130063194362313,6.623627287853577
+radretumab,kappa,HU,scFv-CH,Phase 2,True,2010,,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK,kappa,WHO-INN,PL104,,,151.171797090559,77.0,900.0,9.514,8.69,0.001743,0.1336773168637967,3.38469852929544,8.858000000000002,0.0,1.259503881510183,3.286522462562396
+ramucirumab,kappa,HU,IgG1,Approved,True,2008,,EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSS,DIQMTQSPSSVSASIGDRVTITCRASQGIDNWLGWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIK,kappa,WHO-INN,PL100,,,90.6680959632434,66.0,900.0,9.43,8.705,0.02434,0.0,0.0158442816167506,8.581999999999999,-0.02,1.0548930060222366,1.2499168053244594
+ranibizumab,kappa,ZU,Fab,Approved,True,2004,,EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,kappa,PDB,1CZ8,,,41.4478661761276,65.0,300.0,12.142,18.059,0.0942,0.0,7.925273438937659,10.057999999999998,0.02,1.6071237071180915,3.1381031613976704
+reslizumab,kappa,ZU,IgG4,Approved,False,2001,,EVQLVESGGGLVQPGGSLRLSCAVSGLSLTSNSVNWIRQAPGKGLEWVGLIWSNGDTDYNSAIKSRFTISRDTSKSTVYLQMNSLRAEDTAVYYCAREYYGYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCLASEGISSYLAWYQQKPGKAPKLLIYGANSLQTGVPSRFSGSGSATDYTLTISSLQPEDFATYYCQQSYKFPNTFGQGTKVEVK,kappa,US Patent,US5998586,,,191.56852636743,75.5,700.0,9.824,8.9,0.06217,0.2302901027079426,1.7393013527342458,8.863999999999999,0.0,1.2514632393209744,2.0232945091514143
+rilotumumab,kappa,HU,IgG2,Phase 3,False,2009,,QVQLQESGPGLVKPSETLSLTCTVSGGSISIYYWSWIRQPPGKGLEWIGYVYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYYCARGGYDFWSGYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVDSNLAWYRQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYINWPPITFGQGTRLEIK,kappa,WHO-INN,PL101,,,173.0777953220001,79.0,500.0,12.633,17.684,1.2728,0.1600219342634753,2.126579585174486,10.393,0.0,1.130870798292275,2.3730337078651687
+rituximab,kappa,XI,IgG1,Approved,False,1997,,QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA,QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIK,kappa,PDB,2OSL,,,164.141012459454,69.0,700.0,10.797,9.109,0.025,0.3838657467640554,2.1331376064924,10.146999999999998,-0.01,1.1902969075892451,2.929118136439268
+robatumumab,kappa,HU,IgG1,Phase 2,False,2008,,EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWISVIDTRGATYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLGNFYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSVSPGERATLSCRASQSIGSSLHWYQQKPGQAPRLLIKYASQSLSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQSSRLPHTFGQGTKVEIK,kappa,WHO-INN,PL100,,,117.115691209503,80.0,0.0,9.507,8.969,0.04534,0.2666565076523404,29.64509490013043,9.752,0.14,5.219351315649218,8.246256239600665
+romosozumab,kappa,ZU,IgG2,Phase 3,False,2011,,EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMHWVRQAPGQGLEWMGEINPNSGGAGYNQKFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARLGYDDIYDDWYFDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDTLPYTFGGGTKVEIK,kappa,WHO-INN,PL106,,,227.687243355563,76.0,1000.0,9.18,8.648,0.02831,0.0,-1.019466113704991,8.426999999999998,-0.03,1.0073451432896825,1.4682196339434277
+sarilumab,kappa,HU,IgG1,Phase 3,False,2011,,EVQLVESGGGLVQPGRSLRLSCAASRFTFDDYAMHWVRQAPGKGLEWVSGISWNSGRIGYADSVKGRFTISRDNAENSLFLQMNGLRAEDTALYYCAKGRDSFDIWGQGTMVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFASYYCQQANSFPYTFGQGTKLEIK,kappa,WHO-INN,PL106,,,181.786077494252,64.0,900.0,8.989,8.687,0.04986,0.0,1.1138239186948329,8.71,-0.01,1.1869120226240375,2.16838602329451
+secukinumab,kappa,HU,IgG1,Approved,False,2009,,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMNWVRQAPGKGLEWVAAINQDGSEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDILTDYYIHYWYFDLWGRGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPCTFGQGTRLEIK,kappa,WHO-INN,PL102,,,148.958795741179,72.0,800.0,11.389,8.906,0.0492,0.0,-0.5847129696615325,8.360999999999999,-0.04,1.0888623977969765,1.694756554307116
+seribantumab,lambda,HU,IgG2,Phase 2,True,2012,,EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYVMAWVRQAPGKGLEWVSSISSSGGWTLYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGLKMATIFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNVVSWYQQHPGKAPKLIIYEVSQRPSGVSNRFSGSKSGNTASLTISGLQTEDEADYYCCSYAGSSIFVIFGGGTKVTVL,lambda,WHO-INN,PL108,,,189.983139937075,77.5,300.0,10.418,8.998,0.1544,0.0,21.20826376243033,9.787,0.01,1.2374308746890108,2.9737104825291185
+sifalimumab,kappa,HU,IgG1,Phase 2,False,2009,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYSISWVRQAPGQGLEWMGWISVYNGNTNYAQKFQGRVTMTTDTSTSTAYLELRSLRSDDTAVYYCARDPIAAGYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK,kappa,WHO-INN,PL101,,,158.632741637798,67.0,800.0,9.651,8.773,0.01314,0.0606202186783564,2.1004838375769133,9.019999999999998,-0.02,2.595419081069245,2.497171381031614
+siltuximab,kappa,XI,IgG1,Approved,False,2008,,EVQLVESGGKLLKPGGSLKLSCAASGFTFSSFAMSWFRQSPEKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLEMSSLRSEDTAMYYCARGLWGYYALDYWGQGTSVTVSS,QIVLIQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQWSGYPYTFGGGTKLEIK,kappa,WHO-INN,PL100,,,95.6671732503288,64.5,600.0,10.999,12.076,0.0133,0.0,2.63765782682196,9.419999999999998,-0.01,1.1753257510105992,1.5498127340823968
+simtuzumab,kappa,ZU,IgG4-CPPC,Phase 2,False,2012,,QVQLVQSGAEVKKPGASVKVSCKASGYAFTYYLIEWVRQAPGQGLEWIGVINPGSGGTNYNEKFKGRATITADKSTSTAYMELSSLRSEDTAVYFCARNWMNFDYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSKSLLHSNGNTYLYWFLQKPGQSPQFLIYRMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQHLEYPYTFGGGTKVEIK,kappa,WHO-INN,PL107,,,191.43536575903,66.5,800.0,10.407,9.571,0.1421,0.3368752194611134,0.8806858247165398,9.098,0.0,6.008055924888647,10.411314475873544
+sirukumab,kappa,HU,IgG1,Phase 3,True,2011,,EVQLVESGGGLVQPGGSLRLSCAASGFTFSPFAMSWVRQAPGKGLEWVAKISPGGSWTYYSDTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQLWGYYALDIWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCSASISVSYMYWYQQKPGQAPRLLIYDMSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCMQWSGYPYTFGGGTKVEIK,kappa,WHO-INN,PL105,,,109.80671187862,68.0,0.0,11.26,10.756,0.03969,0.3598739363069841,29.64509490013043,10.79,0.08,2.174539424074148,9.657903494176374
+tabalumab,kappa,HU,IgG4-CPPC,Phase 3,False,2011,,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGYYDILTGYYYYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDSTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK,kappa,WHO-INN,PL105,,,121.595499055525,64.0,700.0,10.847,9.87,0.0618,0.0,1.9553606921790132,9.126999999999995,-0.01,1.2603857827328724,3.6818635607321126
+tanezumab,kappa,ZU,IgG2,Phase 3,True,2008,,QVQLQESGPGLVKPSETLSLTCTVSGFSLIGYDLNWIRQPPGKGLEWIGIIWGDGTTDYNSAVKSRVTISKDTSKNQFSLKLSSVTAADTAVYYCARGGYWYATSYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISNNLNWYQQKPGKAPKLLIYYTSRFHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQEHTLPYTFGQGTKLEIK,kappa,PDB,4EDW,,,48.8637659879149,75.5,700.0,12.386,10.689,0.0166,0.2296116987050972,2.171174192066317,9.247999999999996,-0.01,1.3963581317475169,4.827715355805243
+teplizumab,kappa,ZU,IgG1AA-mut,Phase 3,False,2007,,QVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISRDNSKNTAFLQMDSLRPEDTGVYFCARYYDDHYCLDYWGQGTPVTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQIT,kappa,WHO-INN,PL97,,,150.875164847252,64.5,1000.0,8.786,8.647,0.06126,0.3112823502113737,11.16712056040071,9.364999999999997,0.02,1.6739762600577706,3.8449251247920126
+tigatuzumab,kappa,ZU,IgG1,Phase 2,False,2007,,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMSWVRQAPGKGLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARRGDSMITTDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSYRTFGQGTKVEIK,kappa,WHO-INN,PL98,,,178.9678004885262,64.5,700.0,10.02,8.732,0.0029,0.1287699032014038,5.48928624336508,8.7,-0.01,1.1729393976465865,1.702621722846442
+tildrakizumab,kappa,ZU,IgG1,Phase 3,False,2012,,QVQLVQSGAEVKKPGASVKVSCKASGYIFITYWMTWVRQAPGQGLEWMGQIFPASGSADYNEKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGGGGFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSENIYSYLAWYQQKPGKAPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGIPFTFGQGTKVEIK,kappa,WHO-INN,PL108,,,181.888072908582,77.5,600.0,11.079,9.868,-0.005,0.0,0.8149033177938515,8.727999999999996,-0.01,1.1862533869555876,1.7690515806988354
+tocilizumab,kappa,ZU,IgG1,Approved,False,2004,,QVQLQESGPGLVRPSQTLSLTCTVSGYSITSDHAWSWVRQPPGRGLEWIGYISYSGITTYNPSLKSRVTMLRDTSKNQFSLRLSSVTAADTAVYYCARSLARTTAMDYWGQGSLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQGNTLPYTFGQGTKVEIK,kappa,US Patent,US5795965,,,139.649467055541,91.5,900.0,9.088,8.777,0.04516,0.0,1.3182827059504585,8.902,0.0,1.135550122276806,2.8079866888519134
+tovetumab,kappa,HU,IgG2,Phase 2,False,2013,,QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMNWIRQAPGKGLEWVSYISSSGSIIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGRIAARGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVSITCRPSQSFSRYINWYQQKPGKAPKLLIHAASSLVGGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTYSNPPITFGQGTRLEMK,kappa,WHO-INN,PL109,,,277.1807519763495,63.5,900.0,8.673,8.634,0.0131,0.0,2.24515352101381,8.808,-0.01,1.3521453590768024,2.951685393258427
+tralokinumab,lambda,HU,IgG4,Phase 3,True,2009,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGLSWVRQAPGQGLEWMGWISANNGDTNYGQEFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDSSSSWARWFFDLWGRGTLVTVSS,SYVLTQPPSVSVAPGKTARITCGGNIIGSKLVHWYQQKPGQAPVLVIYDDGDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDTGSDPVVFGGGTKLTVL,lambda,WHO-INN,PL102,,,121.427053055544,63.0,800.0,10.262,8.987,0.007743,0.1573940014543203,4.813687111140356,8.799999999999999,0.09,1.2862877834978763,2.3154742096505823
+trastuzumab,kappa,ZU,IgG1,Approved,False,1997,,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,kappa,WHO-INN,PL103_ADC,Sequences taken from trastuzumab emtansine; identical to trastuzumab from other sources,,159.477626783881,78.5,800.0,9.657,8.752,0.04383,0.0,2.0381268958261267,8.843000000000002,-0.02,1.063454607533758,1.3364392678868553
+tremelimumab,kappa,HU,IgG2,Phase 3,False,2005,,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYSTPFTFGPGTKVEIK,kappa,US Patent,US6682736,,,229.592510711403,75.0,0.0,11.557,19.316,0.01757,0.1454971033487143,29.64509490013043,11.242,0.0,1.2112385448287972,1.965391014975041
+urelumab,kappa,HU,IgG4,Phase 2,False,2010,,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQSPEKGLEWIGEINHGGYVTYNPSLESRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDYGPGNYDWYFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPALTFGGGTKVEIK,kappa,WHO-INN,PL104,VL sequence modified at one position to match patent document (US7659384) and JK germline,,143.923958410927,66.0,0.0,11.161,12.985,0.01389,0.0,29.64509490013043,9.368999999999998,0.07,1.1463753799390732,1.5314475873544091
+ustekinumab,kappa,HU,IgG1,Approved,False,2008,,EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWLGWVRQMPGKGLDWIGIMSPVDSDIRYSPSFQGQVTMSVDKSITTAYLQWNSLKASDTAMYYCARRRPGQGYFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPYTFGQGTKLEIK,kappa,PDB,3HMW,,,152.722928253076,69.5,1000.0,8.783,8.64,0.02254,0.1536533707949192,0.4242355921805543,8.632999999999997,-0.01,2.184532464212374,5.074209650582363
+vedolizumab,kappa,ZU,IgG1AA-mut,Approved,False,2008,,QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLAKSYGNTYLSWYLQKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPYTFGQGTKVEIK,kappa,WHO-INN,PL100,,,221.762037454388,80.5,600.0,10.942,12.307,0.06906,0.0,0.3881784429681827,8.986,-0.02,1.1526713187714972,1.584026622296173
+veltuzumab,kappa,ZU,IgG1,Phase 2,False,2007,,QVQLQQSGAEVKKPGSSVKVSCKASGYTFTSYNMHWVKQAPGQGLEWIGAIYPGMGDTSYNQKFKGKATLTADESTNTAYMELSSLRSEDTAFYYCARSTYYGGDWYFDVWGQGTTVTVSS,DIQLTQSPSSLSASVGDRVTMTCRASSSVSYIHWFQQKPGKAPKPWIYATSNLASGVPVRFSGSGSGTDYTFTISSLQPEDIATYYCQQWTSNPPTFGGGTKLEIK,kappa,WHO-INN,PL98,,,224.9535174226083,70.0,700.0,11.092,9.725,0.0399,0.0,4.831871310872237,8.791999999999998,-0.02,0.8888091523389052,1.2112359550561798
+visilizumab,kappa,ZU,IgG2,Phase 3,False,2000,,QVQLVQSGAEVKKPGASVKVSCKASGYTFISYTMHWVRQAPGQGLEWMGYINPRSGYTHYNQKLKDKATLTADKSASTAYMELSSLRSEDTAVYYCARSAYYDYDGFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQKPGKAPKRLIYDTSKLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSSNPPTFGGGTKVEIK,kappa,US Patent,US7381803,,,242.006376767476,71.0,0.0,9.007,8.695,0.0576,0.4180705492837355,21.98819305835164,9.146,0.01,1.8807718205977448,4.799334442595674
+zalutumumab,kappa,HU,IgG1,Phase 3,False,2005,,QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,kappa,US Patent,US8586041,,,200.506689606493,72.5,900.0,9.335,8.738,0.04983,0.0,-0.796790150018558,8.414999999999997,-0.03,1.2843634959160908,2.896505823627288
+zanolimumab,kappa,HU,IgG1,Phase 3,False,2004,,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARVINWFDPWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQDISSWLAWYQHKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPYTFGQGTKLEIK,kappa,US Patent,US7722873,,,116.367687863994,80.5,700.0,9.586,8.768,0.02569,0.1271277252105276,1.4579366607851665,8.609999999999998,-0.01,1.1022619931841997,1.4555740432612314